Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moodamin in Substance-Induced Depressive Disorder
NCT06790823Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2022
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Substance-induced depressive disorder (SMIDD) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Beck Depression Inventory at 4 weeks. Started Jul 2022; status: completed.
02
Conditions
Substance-induced depressive disorder (SMIDD)
Beyond the preview
Go deeper on NCT06790823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790823.